Esophageal cancer accounts for the sixth leading cause of cancer-related deaths worldwide. The clinical efficacy of therapies for esophageal squamous-cell carcinoma (ESCC) remain limited due to drug resistance and side effects. There is an urgent need to identify new therapeutic targets to shed light on its pathogenesis.